Targeting NKG2A to boost anti-tumor CD8 T-cell responses in human colorectal cancer

Recently, the inhibitory CD94/NKG2A receptor has joined the group of immune checkpoints (ICs) and its expression has been documented in NK cells and CD8(+) T lymphocytes in several cancers and some infectious diseases. In colorectal cancer (CRC), we previously reported that NKG2A(+) tumor-infiltrati...

Descripción completa

Detalles Bibliográficos
Autores principales: Ducoin, Kathleen, Oger, Romain, Bilonda Mutala, Linda, Deleine, Cécile, Jouand, Nicolas, Desfrançois, Juliette, Podevin, Juliette, Duchalais, Emilie, Cruard, Jonathan, Benlalam, Houssem, Labarrière, Nathalie, Bossard, Céline, Jarry, Anne, Gervois-Segain, Nadine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8920231/
https://www.ncbi.nlm.nih.gov/pubmed/35295095
http://dx.doi.org/10.1080/2162402X.2022.2046931

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8920231/
https://www.ncbi.nlm.nih.gov/pubmed/35295095
http://dx.doi.org/10.1080/2162402X.2022.2046931

Ejemplares similares